YOLFTbeta
Fractyl Health, Inc. Common Stock

Fractyl Health, Inc. Common Stock

GUTS · NASDAQ · Healthcare / Biotechnology

0.9036USD+0.09 (+11.27%)

Price History

Full chart

Market Stats

Previous Close0.8121
Open0.85
Day Range0.8412 – 0.95
52-Week Range0.377 – 2.45
Volume421.75K
Market Cap74.80M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.91
Dividend Yield0.00%
Beta2.33
50-Day Avg0.6942
200-Day Avg0.9123

About

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jay D. Caplan BSEE, MBA
  • Employees100
  • Headquarters3 Van de Graaff Drive, Burlington, MA, United States, 01803, USA
  • Websitehttps://fractyl.com

Leadership

  • Mr. Jay D. Caplan BSEE, MBACo-Founder, Chief Product Officer & President · b. 1962
  • Ms. Sarah S. Toomey Esq.General Counsel & Corporate Secretary · b. 1975
  • Ms. Lara Smith WeberCFO & Treasurer · b. 1975
  • Mr. Brian LuqueHead of Investor Relations & Corporate Development
  • Mr. Jon FitzgeraldSenior Vice President of Regulatory, Quality & Clinical
  • Mr. Mike ZumdahlSenior Vice President of Market Access & Commercial Strategy

Financials

Income Statement

Currency: USD2019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Revenue-000120.00K93.00K0
Growth (%)------22.50%-100.00%
Cost of Revenue893.00K770.00K676.00K452.00K77.00K50.00K1.13M
Gross Profit-893.00K-770.00K-676.00K-452.00K43.00K43.00K-1.13M
Gross Margin----35.83%46.24%-
Operating Expense29.03M28.19M36.25M48.93M50.88M93.57M95.69M
Operating Income-29.92M-28.96M-36.93M-49.38M-50.84M-93.53M-96.82M
Operating Margin-----42363.33%-100570.97%-
EBITDA-29.03M-28.19M-36.62M-46.00M-50.55M-68.02M-139.82M
EBITDA Margin-----42125.00%-73136.56%-
Net Income-30.59M-30.48M-38.73M-46.45M-77.09M-68.69M-140.95M
Net Income Margin-----64242.50%-73864.52%-
R&D20.89M22.43M26.43M34.35M38.04M70.47M74.54M
R&D as % of Total Revenue----31698.33%75775.27%-
Interest Expense635.00K1.50M1.44M----

Balance Sheet

Currency: USD2019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Assets8.93M34.76M102.55M60.96M76.21M108.08M121.40M
Total Liabilities152.93M19.81M311.87M313.27M401.27M79.65M111.94M
Total Equity-144.00M14.95M-209.32M-252.32M-325.06M28.42M9.46M
Cash5.79M29.11M95.47M49.27M33.21M67.46M81.54M
Total Debt14.90M15.29M304.34M306.81M86.39M62.50M61.65M
Net Debt9.11M-13.81M208.87M257.54M53.18M-4.96M-19.89M

Cash Flow

Currency: USD2019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Operating Cash Flow-27.73M-31.07M-33.46M-46.24M-42.82M-65.52M-90.33M
Investing Cash Flow-97.00K-2.00K-51.00K-56.00K--1.76M-557.00K
Financing Cash Flow15.16M54.39M99.88M4.35M27.44M101.23M104.96M
Capital Expenditure97.00K2.00K51.00K56.00K359.00K1.76M557.00K
Free Cash Flow-27.83M-31.07M-33.51M-46.30M-43.18M-67.29M-90.89M
FCF to OCF100.35%100.01%100.15%100.12%100.84%102.69%100.62%

Earnings

Report DateMay 13, 2024Aug 14, 2024Nov 12, 2024Mar 3, 2025May 13, 2025Aug 12, 2025Nov 12, 2025Mar 24, 2026Apr 6, 2026Aug 10, 2026Nov 11, 2026
EPS Estimate-0.30-0.46-0.50-0.42-0.50-0.36-0.32-0.18-0.41-0.15-0.13
EPS Actual-0.17-0.36-0.43-0.52-0.49-0.57-0.71-0.070.06-0.12-
Surprise43.33%21.74%14.00%-23.81%2.00%-58.33%-121.88%61.11%114.20%20.00%-
TimingAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap74.80M
Enterprise Value90.34M
Trailing P/E0.00
Forward P/E0.00
Price / Sales4489.16
Price / Book5.06
EPS-0.91
Book Value-0.01
Revenue (TTM)3.00K
Gross Profit (TTM)3.00K
EBITDA-84.77M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-778.33%
Return on Assets-74.57%
Shares Outstanding159.18M
Shares Float145.73M
Beta2.33
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 4 analystsTarget 5.03
  • Strong Buy
    3
  • Buy
    1

Ownership Breakdown

Institutions
51.51%
Insiders
1.40%
Retail / Other
47.09%

Top Institutional Holders

  • Nantahala Capital Management, LLC
    13.36M8.40%
  • 683 Capital Management LLC
    6.73M4.23%
  • Catalio Capital Management, LP
    6.17M3.88%
  • Vanguard Capital Management, LLC
    5.53M3.48%
  • Pale Fire Capital SE
    5.00M3.14%
  • General Catalyst Group Management, LLC
    4.88M3.07%
  • Deer Management Co. LLC
    4.77M3.00%
  • Maverick Capital Ltd
    3.97M2.50%
  • Woodline Partners LP
    2.24M1.41%
  • BlackRock Inc
    2.14M1.34%
  • M28 Capital Management LP
    1.86M1.17%
  • SILVERARC CAPITAL MANAGEMENT, LLC
    1.70M1.07%
  • UBS Group AG
    1.62M1.02%
  • Geode Capital Management, LLC
    1.44M0.90%
  • CM Management, LLC
    1.40M0.88%
  • Ikarian Capital, LLC
    1.10M0.69%
  • Logos Global Management LP
    1.00M0.63%
  • Marshall Wace Asset Management Ltd
    807.80K0.51%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    4.62M2.90%
  • Abante Quant Value FI
    715.60K0.45%